Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

4,704 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Phase I safety and pharmacokinetic study of YM155, a potent selective survivin inhibitor, in combination with erlotinib in patients with EGFR TKI refractory advanced non-small cell lung cancer.
Shimizu T, Nishio K, Sakai K, Okamoto I, Okamoto K, Takeda M, Morishita M, Nakagawa K. Shimizu T, et al. Among authors: nakagawa k. Cancer Chemother Pharmacol. 2020 Aug;86(2):211-219. doi: 10.1007/s00280-020-04112-1. Epub 2020 Jul 8. Cancer Chemother Pharmacol. 2020. PMID: 32638093 Clinical Trial.
Ritterazine B, a new cytotoxic natural compound, induces apoptosis in cancer cells.
Komiya T, Fusetani N, Matsunaga S, Kubo A, Kaye FJ, Kelley MJ, Tamura K, Yoshida M, Fukuoka M, Nakagawa K. Komiya T, et al. Among authors: nakagawa k. Cancer Chemother Pharmacol. 2003 Mar;51(3):202-8. doi: 10.1007/s00280-002-0558-8. Epub 2003 Jan 14. Cancer Chemother Pharmacol. 2003. PMID: 12655437
Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].
Fukuoka M, Yano S, Giaccone G, Tamura T, Nakagawa K, Douillard JY, Nishiwaki Y, Vansteenkiste J, Kudoh S, Rischin D, Eek R, Horai T, Noda K, Takata I, Smit E, Averbuch S, Macleod A, Feyereislova A, Dong RP, Baselga J. Fukuoka M, et al. Among authors: nakagawa k. J Clin Oncol. 2003 Jun 15;21(12):2237-46. doi: 10.1200/JCO.2003.10.038. Epub 2003 May 14. J Clin Oncol. 2003. PMID: 12748244 Corrected and republished. Clinical Trial.
[Subset analysis of data in the Japanese patients with NSCLC from IDEAL 1 study on gefitinib].
Nishiwaki Y, Yano S, Tamura T, Nakagawa K, Kudoh S, Horai T, Noda K, Takata I, Watanabe K, Saka H, Takeda K, Imamura F, Matsui K, Katakami N, Yokoyama A, Sawa Y, Takada M, Kiura K, Sugiura T, Fukuoka M, Uchida H. Nishiwaki Y, et al. Among authors: nakagawa k. Gan To Kagaku Ryoho. 2004 Apr;31(4):567-73. Gan To Kagaku Ryoho. 2004. PMID: 15114701 Clinical Trial. Japanese.
A phase I/II study comparing regimen schedules of gemcitabine and docetaxel in Japanese patients with stage IIIB/IV non-small cell lung cancer.
Matsui K, Hirashima T, Nitta T, Kobayashi M, Ogata Y, Furukawa M, Kudoh S, Yoshimura N, Mukohara T, Yamauchi S, Shiraishi S, Kamoi H, Negoro S, Takeda K, Nakagawa K, Takada M, Yana T, Fukuoka M. Matsui K, et al. Among authors: nakagawa k. Jpn J Clin Oncol. 2005 Apr;35(4):181-7. doi: 10.1093/jjco/hyi057. Jpn J Clin Oncol. 2005. PMID: 15845566 Clinical Trial.
EKB-569, a new irreversible epidermal growth factor receptor tyrosine kinase inhibitor, with clinical activity in patients with non-small cell lung cancer with acquired resistance to gefitinib.
Yoshimura N, Kudoh S, Kimura T, Mitsuoka S, Matsuura K, Hirata K, Matsui K, Negoro S, Nakagawa K, Fukuoka M. Yoshimura N, et al. Among authors: nakagawa k. Lung Cancer. 2006 Mar;51(3):363-8. doi: 10.1016/j.lungcan.2005.10.006. Epub 2005 Dec 20. Lung Cancer. 2006. PMID: 16364494 Clinical Trial.
4,704 results